Wolverine Stack Dosage in the Research Literature

BPC-157 dosage in animal studies follows a consistent range across the published literature. The most common dose in rat musculoskeletal models is 10 µg/kg intraperitoneal, with equipotent effects also observed at 10 ng/kg and, in some tendon models, at 10 pg/kg.^[1][2] Oral administration in drinking water has been studied at 0.16 µg/mL (approximately 12 mL per rat per day) and at 10 µg/kg per oral in muscle-to-bone reattachment models.^[6][7] Topical administration was studied at 1 µg/g neutral cream in burn wound models.^[20] In gastric ulcer models, intramuscular doses of 200–800 ng/kg were used.^[11]

BPC-157 is notable for its gastric stability — the peptide resists degradation by trypsin and chymotrypsin, enabling oral administration effectiveness in rat models. Most peptides are inactivated by these enzymes within seconds; BPC-157 remains stable in human gastric juice for more than 24 hours.^[18]

For TB-500 (thymosin beta-4 fragment), published preclinical dosing is based primarily on studies using full-length thymosin beta-4. The dystrophin-deficient mouse study used 150 µg twice weekly over 6 months via intraperitoneal injection.^[16] Human Phase 2 trials used topical formulations for wound and ulcer endpoints; a Phase 1 intravenous safety study was conducted (NCT00743769). The TB-500 fragment sold by research vendors is not identical to full-length thymosin beta-4 — most mechanistic research uses full-length Tβ4 or the LKKTET hexapeptide, creating an inference gap for direct TB-500 dosing comparisons.

The Wolverine stack research protocol — as a concept derived from the published literature — describes what individual studies have used for each component, not a unified validated protocol for the combination.

For BPC-157, the most reproducible preclinical protocol across independent publications is daily intraperitoneal injection at 10 µg/kg starting at the time of injury induction, with functional and histological endpoints assessed at 7 days (acute) to 90 days (chronic repair).^[1][2][6] Some models applied BPC-157 orally in drinking water, demonstrating equivalent efficacy via a different route.^[6][7]

For thymosin beta-4, the most extended preclinical protocol used twice-weekly intraperitoneal injections of 150 µg over 6 months in a chronic disease model.^[16] Acute wound healing protocols used topical application with assessment at 4–7 days.^[22]

The Wolverine stack protocol overview does not represent a validated co-administration schedule — no published study has defined one.

No peer-reviewed study has formally optimized the BPC-157:TB-500 ratio in combination. The 1:1 ratio commonly described in community discussions is an anecdotal convention, not a research-derived recommendation.^[18]

The two compounds have been dosed at substantially different absolute amounts in their respective independent studies: BPC-157 at doses in the microgram-per-kilogram range (as low as 10 pg/kg with reported activity); TB-500 at 150 µg per injection in the mouse model. Direct ratio comparisons are further complicated by the inference gap between the TB-500 fragment and the full-length thymosin beta-4 used in most mechanistic studies.

BPC-157 pharmacokinetics in rats and dogs showed linear, dose-proportional characteristics. Intravenous half-life was less than 30 minutes — mean 15.2 minutes in rats and 5.27 minutes in dogs.^[17] Intramuscular bioavailability was 14–19% in rats and 45–51% in dogs. The compound was rapidly metabolized to small peptide fragments and individual amino acids, excreted via urine and bile.^[17]

Oral administration in rat models is associated with a substantially longer apparent pharmacokinetic profile — reported at approximately 66–69 hours in some analyses — likely reflecting a different absorption and distribution model rather than the same distribution seen intravenously. BPC-157's resistance to trypsin and chymotrypsin degradation is the key factor enabling oral bioactivity in rats.^[18]

Human pharmacokinetics for BPC-157 have not been formally characterized. No Phase 1 pharmacokinetic study has been published.

Preclinical study durations span a wide range depending on the injury model and endpoint. BPC-157 studies in acute tendon and ligament models use 7-day early assessment windows, with full biomechanical endpoints at 28–90 days.^[1][2] Chronic injury models — including the spinal cord compression study that applied BPC-157 at day 4 of an established injury — assessed recovery by day 15.^[9]

For the thymosin beta-4 muscle regeneration model, the study duration was 6 months — consistent with the timeline required to assess fiber-count changes in a dystrophic disease model.^[16]

No standardized cycle length is established for the Wolverine stack combination in peer-reviewed literature. Community-described "research cycles" of 4–12 weeks are anecdotal conventions with no published optimization basis.

Circadian timing effects on BPC-157 or TB-500 activity have not been systematically studied in the published literature. No time-of-day preference — morning versus night administration — is established in any preclinical data for either compound. The published studies have used standardized injection schedules without reference to circadian variables.

Animal models show measurable tissue-repair markers at 7–14 days in acute injury models; functional and biomechanical recovery endpoints are typically assessed at 28–90 days in musculoskeletal studies.^[1][2] No validated human timeline data exists for the Wolverine stack combination.